Abstract
Metastatic disease is responsible for most of cancer lethality. A main obstacle for therapy of advanced cancers is that the outcome of metastasis depends on a complex interplay between malignant and host cells. The perioperative period represents an underutilized window of opportunity for cancer treatment where tumor-host interactions can be modulated, reducing the risk of local recurrences and distant metastases. Blood-saving agents are attractive compounds to be administered during tumor surgery. Desmopressin (DDAVP) is a safe and convenient hemostatic peptide with proved antimetastastic properties in experimental models and veterinary clinical trials. The compound seems to induce a dual angiostatic and antimetastatic effect, breaking the cooperative function of cancer cells and endothelial cells during residual tumor progression. DDAVP is therefore an interesting lead compound to develop novel synthetic peptide analogs with enhanced antitumor properties.
Keywords: Angiogenesis, breast cancer, desmopressin, hemostasis, Surgery, tumor spread, vasopressin analog, cancer lethality, hemostatic peptide, veterinary clinical trials, synthetic peptide analogs, blood vessels, occult neoplastic cells, colonic stents, preclinical models
Current Pharmaceutical Biotechnology
Title: Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Volume: 12 Issue: 11
Author(s): D. F. Alonso, G. V. Ripoll, J. Garona, N. B. Iannucci and D. E. Gomez
Affiliation:
Keywords: Angiogenesis, breast cancer, desmopressin, hemostasis, Surgery, tumor spread, vasopressin analog, cancer lethality, hemostatic peptide, veterinary clinical trials, synthetic peptide analogs, blood vessels, occult neoplastic cells, colonic stents, preclinical models
Abstract: Metastatic disease is responsible for most of cancer lethality. A main obstacle for therapy of advanced cancers is that the outcome of metastasis depends on a complex interplay between malignant and host cells. The perioperative period represents an underutilized window of opportunity for cancer treatment where tumor-host interactions can be modulated, reducing the risk of local recurrences and distant metastases. Blood-saving agents are attractive compounds to be administered during tumor surgery. Desmopressin (DDAVP) is a safe and convenient hemostatic peptide with proved antimetastastic properties in experimental models and veterinary clinical trials. The compound seems to induce a dual angiostatic and antimetastatic effect, breaking the cooperative function of cancer cells and endothelial cells during residual tumor progression. DDAVP is therefore an interesting lead compound to develop novel synthetic peptide analogs with enhanced antitumor properties.
Export Options
About this article
Cite this article as:
F. Alonso D., V. Ripoll G., Garona J., B. Iannucci N. and E. Gomez D., Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798377076
DOI https://dx.doi.org/10.2174/138920111798377076 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews The Vascular Component of Alzheimer`s Disease
Current Neurovascular Research Physical Function and Exercise in Older Patients with Cardiovascular and Respiratory Conditions
Current Pharmaceutical Design Coagulopathy as a Therapeutic Target for TRALI: Rationale and Possible Sites of Action
Current Pharmaceutical Design Remote Ischemic Conditioning Improves Cognitive Function During Cerebral Vascular Injury Through the Induction of Autophagy
Current Neurovascular Research Therapeutic Perspectives in the Antiphospholipid Syndrome
Current Rheumatology Reviews Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Synthesis, Anticlotting and Antiplatelet Effects of 1,2,3-Triazoles Derivatives
Medicinal Chemistry Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Review of the Biological Activity of Maslinic Acid
Current Drug Targets Thrombolytic Agents for Acute Ischaemic Stroke Treatment: The Past, Present and Future
CNS & Neurological Disorders - Drug Targets Crosstalk between Inflammation and Coagulation: The Lessons of Sepsis
Current Vascular Pharmacology Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Platelets in Angiogenesis
Current Vascular Pharmacology Therapeutic Angiogenesis in Ischemic Tissues by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects
Current Stem Cell Research & Therapy Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology The Impact of Coagulation and Fibrinolysis Cascades on the Development of Septic and Autoimmune Arthritis
Current Rheumatology Reviews